DDIT3 and diffuse large B-cell lymphoma: After approval of the chimeric anti‐CD20 antibody, rituximab, R‐CHOP has been established as the first‐line treatment for DLBCL based on the results of several randomized phase III studies.4, 5 The current standard therapy for DLBCL with gastric lesions (DLBCL‐GL) is six to eight cycles of R‐CHOP or three cycles of R‐CHOP followed by involved‐field radiation therapy (IFRT) for early‐stage disease.